Literature DB >> 18090908

Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.

Pavol Zubor1, Karol Kajo, Andrea Stanclova, Norbert Szunyogh, Silvester Galo, Carlos A Dussan, Gabriel Minarik, Jozef Visnovsky, Jan Danko.   

Abstract

Studies on the association between the Ile to Val polymorphism at codon 655 of the human epithelial growth factor receptor 2 (HER-2) gene and susceptibility to breast cancer have been reported for almost all ethnic populations, with both positive or negative conclusions. No study, however, has yet been focused on the possible association between this gene and its predisposition to benign breast lesions, especially on risk for fibroadenoma. We aimed to study the association of the single nucleotide polymorphism V655 HER-2 gene polymorphism with histologically verified breast fibroadenoma risk. We conducted a molecular epidemiological case-control study of 70 breast fibroadenoma cases without cellular atypia and 172 healthy female controls. We found that the Val variant allele and genotype frequency of this polymorphism is higher in cases with fibroadenoma; however, this difference was not significant (allele Val 655: 27.86 and 22.67% in fibroadenoma and controls, respectively; genotype Ile/Val: 35.71 and 38.37% and Val/Val: 10.0 and 3.49% in fibroadenoma and controls, respectively). Applying logistic regression analysis, we found an increased risk of fibroadenoma formation in carriers of the Val allele (odds ratio = 1.17; 95% confidence interval = 0.67-2.05), in which the highest risk was associated with homozygous genotype (odds ratio = 3.07; 95% confidence interval = 0.97-9.72), but this risk was not significant. Stratification by age (cut-off 45 years) revealed the highest risk of fibroadenoma among young women homozygous for the Val allele (odds ratio = 3.30). The risk, however, was slightly increased (odds ratio = 1.24) among older carriers of the aberrant allele in their genotype as well, but it was not significant. In spite of insignificant differences, our results indicate that HER-2 Ile655Val polymorphism, especially in a homozygous form might play some role in the etiology of breast fibroadenoma formation. The significance of this susceptibility, however, will have to be verified by larger studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090908     DOI: 10.1097/CEJ.0b013e3280145e4b

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

Review 1.  In vitro assays for the evaluation of drug resistance in tumor cells.

Authors:  Jozef Hatok; Eva Babusikova; Tatiana Matakova; Dusan Mistuna; Dusan Dobrota; Peter Racay
Journal:  Clin Exp Med       Date:  2008-09-26       Impact factor: 3.984

Review 2.  Malignant tumors of the uterine corpus: molecular background of their origin.

Authors:  D Brany; D Dvorska; M Nachajova; P Slavik; T Burjanivova
Journal:  Tumour Biol       Date:  2015-08-26

Review 3.  DNA methylation and detection of cervical cancer and precancerous lesions using molecular methods.

Authors:  Sandra Mersakova; Marcela Nachajova; Peter Szepe; Petra Sumichrastova Kasajova; Erika Halasova
Journal:  Tumour Biol       Date:  2015-10-12

4.  Association of HER2 codon 655 polymorphism with ovarian cancer.

Authors:  Rafał Watrowski; Dan Cacsire Castillo-Tong; Eva Schuster; Michael B Fischer; Paul Speiser; Robert Zeillinger
Journal:  Tumour Biol       Date:  2015-12-14

5.  HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.